{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T15:40:41Z","timestamp":1787586041444,"version":"build-2736575974"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T00:00:00Z","timestamp":1714435200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["21K16317, 21KK0295, 19H03458, JPJSBP120205704, 18K06655, 21K06559"],"award-info":[{"award-number":["21K16317, 21KK0295, 19H03458, JPJSBP120205704, 18K06655, 21K06559"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013996","name":"Global Health Innovative Technology Fund","doi-asserted-by":"publisher","award":["T2021-256"],"award-info":[{"award-number":["T2021-256"]}],"id":[{"id":"10.13039\/501100013996","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Among <jats:italic>Plasmodium<\/jats:italic> spp. responsible for human malaria, <jats:italic>Plasmodium vivax<\/jats:italic> ranks as the second most prevalent and has the widest geographical range; however, vaccine development has lagged behind that of <jats:italic>Plasmodium falciparum<\/jats:italic>, the deadliest <jats:italic>Plasmodium<\/jats:italic> species. Recently, we developed a multistage vaccine for <jats:italic>P. falciparum<\/jats:italic> based on a heterologous prime-boost immunization regimen utilizing the attenuated vaccinia virus strain LC16m8\u0394 (m8\u0394)-prime and adeno-associated virus type 1 (AAV1)-boost, and demonstrated 100% protection and more than 95% transmission-blocking (TB) activity in the mouse model. In this study, we report the feasibility and versatility of this vaccine platform as a <jats:italic>P. vivax<\/jats:italic> multistage vaccine, which can provide 100% sterile protection against sporozoite challenge and &amp;gt;95% TB efficacy in the mouse model. Our vaccine comprises m8\u0394 and AAV1 viral vectors, both harboring the gene encoding two <jats:italic>P. vivax<\/jats:italic> circumsporozoite (PvCSP) protein alleles (VK210; PvCSP-Sal and VK247; -PNG) and P25 (Pvs25) expressed as a Pvs25\u2013PvCSP fusion protein. For protective efficacy, the heterologous m8\u0394-prime\/AAV1-boost immunization regimen showed 100% (short-term; Day 28) and 60% (long-term; Day 242) protection against PvCSP VK210 transgenic <jats:italic>Plasmodium berghei<\/jats:italic> sporozoites. For TB efficacy, mouse sera immunized with the vaccine formulation showed &amp;gt;75% TB activity and &amp;gt;95% transmission reduction activity by a direct membrane feeding assay using <jats:italic>P. vivax<\/jats:italic> isolates in blood from an infected patient from the Brazilian Amazon region. These findings provide proof-of-concept that the m8\u0394\/AAV1 vaccine platform is sufficiently versatile for <jats:italic>P. vivax<\/jats:italic> vaccine development. Future studies are needed to evaluate the safety, immunogenicity, vaccine efficacy, and synergistic effects on protection and transmission blockade in a non-human primate model for Phase I trials.<\/jats:p>","DOI":"10.3389\/fimmu.2024.1372584","type":"journal-article","created":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T04:28:42Z","timestamp":1714451322000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["A two-dose viral-vectored Plasmodium vivax multistage vaccine confers durable protection and transmission-blockade in a pre-clinical study"],"prefix":"10.3389","volume":"15","author":[{"given":"Yutaro","family":"Yamamoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camila","family":"Fabbri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiki","family":"Okuhara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rina","family":"Takagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuna","family":"Kawabata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuto","family":"Katayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuhiro","family":"Iyori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ammar A.","family":"Hasyim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiko","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Mizukami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisatoshi","family":"Shida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Lopes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeto","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,4,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/507s4a","article-title":"Infectious disease: beating the big three","volume":"507","author":"Bourzac","year":"2014","journal-title":"Nature"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0000774","article-title":"The international limits and population at risk of Plasmodium vivax transmission in 2009","volume":"4","author":"Guerra","year":"2010","journal-title":"PloS Negl Trop Dis"},{"key":"B3","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1128\/CMR.00074-12","article-title":"Evidence and implications of mortality associated with acute Plasmodium vivax malaria","volume":"26","author":"Baird","year":"2013","journal-title":"Clin Microbiol Rev"},{"key":"B4","doi-asserted-by":"publisher","first-page":"97","DOI":"10.4269\/ajtmh.2001.64.97","article-title":"The neglected burden of Plasmodium vivax malaria","volume":"64","author":"Mendis","year":"2001","journal-title":"Am J Trop Med Hyg"},{"key":"B5","volume-title":"World Malaria Report 2022","year":"2022"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-10-297","article-title":"Determinants of relapse periodicity in Plasmodium vivax malaria","volume":"10","author":"White","year":"2011","journal-title":"Malar J"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.pt.2007.01.008","article-title":"An update on the search for a Plasmodium vivax vaccine","volume":"23","author":"Herrera","year":"2007","journal-title":"Trends Parasitol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-023-02053-2","article-title":"In search of a vaccine for Plasmodium vivax malaria","volume":"618","author":"Vargas-Parada","year":"2023","journal-title":"Nature"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.parint.2021.102411","article-title":"Plasmodium vivax pre-erythrocytic vaccines","volume":"84","author":"Reyes-Sandoval","year":"2021","journal-title":"Parasitol Int"},{"key":"B10","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1186\/s12936-020-03366-7","article-title":"Genetic polymorphism and natural selection of circumsporozoite protein in Myanmar Plasmodium vivax","volume":"19","author":"Vo","year":"2020","journal-title":"Malar J"},{"key":"B11","doi-asserted-by":"publisher","first-page":"17928","DOI":"10.1038\/s41598-021-96986-1","article-title":"A Universal Vaccine Candidate against Plasmodium Vivax Malaria Confers Protective Immunity against the Three Pvcsp Alleles","volume":"11","author":"Gimenez","year":"2021","journal-title":"Sci Rep"},{"key":"B12","doi-asserted-by":"publisher","first-page":"916","DOI":"10.3390\/microorganisms8060916","article-title":"A multistage formulation based on full-length csp and ama-1 ectodomain of Plasmodium vivax induces high antibody titers and T-cells and partially protects mice challenged with a transgenic Plasmodium berghei parasite","volume":"8","author":"Lima","year":"2020","journal-title":"Microorganisms"},{"key":"B13","doi-asserted-by":"publisher","first-page":"73","DOI":"10.5897\/AJPP2023.5355","article-title":"Genetic diversity of pvcsp and pvs25 in Plasmodium vivax isolates in malaria-endemic areas in Asia, Africa, and America: A systematic review","volume":"17","author":"Guled","year":"2023","journal-title":"Afr J Pharm Pharmacol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(22)00442-X","article-title":"Efficacy and Immunogenicity of R21\/Matrix-M Vaccine against Clinical Malaria after 2 Years' Follow-up in Children in Burkina Faso: A Phase 1\/2b Randomised Controlled Trial","volume":"22","author":"Datoo","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/srep46482","article-title":"Rational development of a protective P. Vivax vaccine evaluated with transgenic rodent parasite challenge models","volume":"7","author":"Salman","year":"2017","journal-title":"Sci Rep"},{"key":"B16","doi-asserted-by":"publisher","first-page":"12","DOI":"10.4269\/ajtmh.2011.09-0516","article-title":"Phase I safety and immunogenicity trial of Plasmodium vivax cs derived long synthetic peptides adjuvanted with montanide isa 720 or montanide isa 51","volume":"84","author":"Herrera","year":"2011","journal-title":"Am J Trop Med Hyg"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1005476","article-title":"Sterile protection and transmission blockade by a multistage anti-malarial vaccine in the pre-clinical study","volume":"13","author":"Iyori","year":"2022","journal-title":"Front Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.612910","article-title":"Liver-directed aav8 booster vaccine expressing Plasmodium falciparum antigen following adenovirus vaccine priming elicits sterile protection in a murine model","volume":"12","author":"Shahnaij","year":"2021","journal-title":"Front Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.02040-14","article-title":"Baculovirus-vectored multistage Plasmodium vivax vaccine induces both protective and transmission-blocking immunities against transgenic rodent malaria parasites","volume":"82","author":"Mizutani","year":"2014","journal-title":"Infect Immun"},{"key":"B20","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1186\/s12936-016-1297-3","article-title":"Development of a Plasmodium berghei transgenic parasite expressing the full-length Plasmodium vivax circumsporozoite vk247 protein for testing vaccine efficacy in a murine model","volume":"15","author":"Mizutani","year":"2016","journal-title":"Malar J"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1590\/0074-02760200513","article-title":"Transmission-blocking compound candidates against Plasmodium vivax using P. Berghei as an initial screening","volume":"116","author":"Fabbri","year":"2021","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"B22","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/s12936-022-04204-8","article-title":"Evaluation of sustainable susceptibility to Plasmodium vivax infection among colonized anopheles darlingi and anopheles deaneorum","volume":"21","author":"Santos","year":"2022","journal-title":"Malar J"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.7883\/yoken.JJID.2017.458","article-title":"A novel system for constructing a recombinant highly-attenuated vaccinia virus strain (Lc16m8) expressing foreign genes and its application for the generation of lc16m8-based vaccines against herpes simplex virus 2","volume":"71","author":"Omura","year":"2018","journal-title":"Jpn J Infect Dis"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1099\/0022-1317-71-6-1293","article-title":"Biological and immunological characterization of influenza virus haemagglutinin expressed from the haemagglutinin locus of vaccinia virus","volume":"71","author":"Itamura","year":"1990","journal-title":"J Gen Virol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02412","article-title":"A viral-vectored multi-stage malaria vaccine regimen with protective and transmission-blocking efficacies","volume":"10","author":"Yusuf","year":"2019","journal-title":"Front Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00890-06","article-title":"Induction of robust immune responses against human immunodeficiency virus is supported by the inherent tropism of adeno-associated virus type 5 for dendritic cells","volume":"80","author":"Xin","year":"2006","journal-title":"J Virol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"3896","DOI":"10.1038\/s41598-018-21369-y","article-title":"Adenovirus-prime and baculovirus-boost heterologous immunization achieves sterile protection against malaria sporozoite challenge in a murine model","volume":"8","author":"Yoshida","year":"2018","journal-title":"Sci Rep"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth.2089","article-title":"Nih image to imagej: 25 years of image analysis","volume":"9","author":"Schneider","year":"2012","journal-title":"Nat Methods"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2013.05.071","article-title":"Immunogenicity and safety of the vaccinia virus lc16m8delta vector expressing siv gag under a strong or moderate promoter in a recombinant bcg prime-recombinant vaccinia virus boost protocol","volume":"31","author":"Sato","year":"2013","journal-title":"Vaccine"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0070819","article-title":"Protective efficacy of baculovirus dual expression system vaccine expressing Plasmodium falciparum circumsporozoite protein","volume":"8","author":"Iyori","year":"2013","journal-title":"PloS One"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1800908","article-title":"Baculovirus-induced fast-acting innate immunity kills liver-stage Plasmodium","volume":"201","author":"Emran","year":"2018","journal-title":"J Immunol"},{"key":"B32","volume-title":"Guia de tratamento da mal\u00e1ria no brasil","author":"Brasil","year":"2021"},{"key":"B33","doi-asserted-by":"publisher","first-page":"38","DOI":"10.4269\/ajtmh.2005.73.5_suppl.0730038","article-title":"Plasmodium vivax: transmission-blocking immunity in a malaria-endemic area of Colombia","volume":"73","author":"Arevalo-Herrera","year":"2005","journal-title":"Am J Trop Med Hyg"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2016.06.066","article-title":"Transmission-blocking activity is determined by transmission-reducing activity and number of control oocysts in Plasmodium falciparum standard membrane-feeding assay","volume":"34","author":"Miura","year":"2016","journal-title":"Vaccine"},{"key":"B35","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s43856-021-00030-2","article-title":"Recent clinical trials inform the future for malaria vaccines","volume":"1","author":"Kurtovic","year":"2021","journal-title":"Commun Med (Lond)"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2008.12.027","article-title":"Process development for the production of an E. Coli produced clinical grade recombinant malaria vaccine for Plasmodium vivax","volume":"27","author":"Bell","year":"2009","journal-title":"Vaccine"},{"key":"B37","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1080\/14760584.2021.1880898","article-title":"Progress towards the development of a P. vivax vaccine","volume":"20","author":"De","year":"2021","journal-title":"Expert Rev Vaccines"},{"key":"B38","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(13)62238-2","article-title":"Malaria vaccine technology roadmap","volume-title":"The Lancet J","author":"Moorthy","year":"2013"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.meegid.2019.05.003","article-title":"Plasmodium vivax ookinete surface protein (Pvs25) is highly conserved among field isolates from five different regions of the Brazilian amazon","volume":"73","author":"Chaves","year":"2019","journal-title":"Infect Genet Evol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0406671102","article-title":"Genetically stable and fully effective smallpox vaccine strain constructed from highly attenuated vaccinia lc16m8","volume":"102","author":"Kidokoro","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"B41","article-title":"Report of the national smallpox vaccination research committee: study of side effects, complications and their treatments","volume":"3","author":"Yamaguchi","year":"1975","journal-title":"Clin Virol."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1372584\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T04:28:49Z","timestamp":1714451329000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1372584\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,30]]},"references-count":41,"alternative-id":["10.3389\/fimmu.2024.1372584"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1372584","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,30]]},"article-number":"1372584"}}